Your shopping cart is currently empty

Lansoprazole (A-65006) is a 2, 2, 2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 500 mg | $45 | In Stock | In Stock | |
| 1 g | $62 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $50 | In Stock | In Stock |
| Description | Lansoprazole (A-65006) is a 2, 2, 2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) |
| In vitro | Lansoprazole significantly attenuates intestinal damage induced by ischemia-reperfusion or indomethacin. Exogenous administration of Lansoprazole can prevent injury to the small intestine caused by ischemia-reperfusion or indomethacin. Lansoprazole inhibits acute inflammatory responses and mucosal injury in rats subjected to ischemia-reperfusion or indomethacin-induced damage. |
| In vivo | Lansoprazole is a potent antisecretory agent that inhibits gastric acid secretion by blocking the stomach's hydrogen/potassium adenosine triphosphatase (H+, K+-ATPase). It suppresses the upregulation of adhesion molecules in blood vessels, neutrophil activation, and the production of pro-inflammatory cytokines from activated endothelial cells. Furthermore, Lansoprazole induces the expression of various genes in gastric epithelial cells, including Phase II detoxifying enzymes (NADPH-quinone oxidoreductase, glutathione S-transferase) and antioxidative stress proteins (HO-1, thioredoxin reductase, and superoxide dismutase). In rat gastric epithelial cells, Lansoprazole upregulates HO-1 expression and exerts anti-inflammatory effects. |
| Synonyms | AG-1749, A-65006 |
| Molecular Weight | 369.36 |
| Formula | C16H14F3N3O2S |
| Cas No. | 103577-45-3 |
| Smiles | CC1=C(CS(=O)C2=NC3=CC=CC=C3N2)N=CC=C1OCC(F)(F)F |
| Relative Density. | 1.5 g/cm3 |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (135.37 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.41 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.